LIdocaine veRsus Sufentanil Anaesthesia in Cardiac Surgery With Cardiopulmonary Bypass

Opioid Free Anaesthesia Clinical Trial

— LISRACC  

Official title:

Opioid Free Anaesthesia in Cardiac Surgery With Cardiopulmonary Bypas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05136794
• Other study ID #: GUINOT 2021-4
• Status: Completed
• Start date: December 1, 2021
• Est. completion date: January 15, 2022

Study information

• Verified date: February 2022
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Since the 90's the concept of morphine sparing and morphine free anaesthesia (OFA) has progressively developed in non-cardiac surgery. The principle is based on the fact that in a sleeping patient a sympathetic reaction marked by hemodynamic modifications does not translate into a painful phenomenon, that a painful phenomenon in a sleeping patient is not memorized, that hormonal stress, the sympathetic reaction and the inflammatory reaction can be controlled by other therapeutic classes than a morphine agent. This therapeutic management would avoid the side effects associated with the use of morphine. In this hypothesis, OFA is more and more practiced in various situations without the real impact in terms of clinical benefit being clearly demonstrated. In cardiac surgery, some centers practice OFA with various protocols.The purpose of this work is to retrospectively evaluate over a defined period the incidence of postoperative complications, length of stay in the ICU/hospital, and death rate between patients managed with/without OFA based on lidocaine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1772
• Est. completion date: January 15, 2022
• Est. primary completion date: January 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

age over 18 years Cardiac surgery with cardiopulmonary bypass performed between January 2019 and June 2021 Exclusion Criteria: LVAD Heart transplantation Incomplete data in relation to outcomes

Related Conditions & MeSH terms

• Opioid Anaesthesia
• Opioid Free Anaesthesia

Intervention

Other:
• Data collection
complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay

Locations

Country	Name	City	State
France	Chu Dijon Bourgogne	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ICU stays (days)	Total stay in ICU in day	Day 30
Secondary	Complications	cardiac, neurological, renal, respiratory, red blood transfusion	Day 30
Secondary	Hospital stays (days)	hospital stay	Day 30